A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

Last updated:
2026-09-26
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF BI 1015550 OVER AT LEAST 52 WEEKS IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES (PF-ILDS)

Intervention/treatment:
NERANDOMILAST (BI 1015550)
Medical condition:
PULMONARY FIBROSIS
Protocol code:
1305-0023
Control number:
265822
Status:
Closed
Approved:
September 15, 2022
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT05321082
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Boehringer Ingelheim, Call Center
Organization
Boehringer Ingelheim
Phone:
018002430127
Sponsor
BOEHRINGER INGELHEIM (CANADA) LTD LTEE

Locations

British Columbia

Kelowna Respirology & Allergy Research
Kelowna, British Columbia, V1Y 3H5
St. Paul's Hospital (Vancouver)
Vancouver, British Columbia, V6Z 1Y6
Vancouver General Hospital
Vancouver, British Columbia, V5Z 1M9

New Brunswick

Dr. Georges-L.-Dumont University Hospital Centre
Moncton, New Brunswick, E1C 2Z3

Ontario

Dr. Syed Anees Medicine Professional Corporation
Windsor, Ontario, N8X 1T3
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, L8N 1Y2

Quebec

Centre Hospitalier de l'Universite de Montreal (CHUM)
Montreal, Quebec, H2X 0A9
CIC Mauricie Inc.
Trois Rivieres, Quebec, G8T 7A1
IUCPQ (Laval University)
Quebec, Quebec, G1V 4G5
McGill University Health Centre (MUHC)
Montreal, Quebec, H4A 3J1

Saskatchewan

Royal University Hospital (Saskatoon)
Saskatoon, Saskatchewan, S7N 0W8

Results

See the results from the trial NCT05321082. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?